CLYM Climb Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1768446 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY-37.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.3%
ROA-28.3%
ROIC (approx.)-31.1%
Asset turnover—
Leverage & solvency
Liabilities / assets3.6%
Debt / equity0.00x
Current ratio26.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $46.71M | $14.34M | $15.41M | $26.21M | $23.32M |
| SG&A expense | $21.17M | $16.02M | $24.86M | $18.92M | $12.35M |
| Operating income | -$67.88M | -$82.02M | -$40.27M | -$45.13M | -$35.67M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.85M | -$73.90M | -$35.12M | -$45.24M | -$47.48M |
| EBITDA | -$67.79M | -$82.02M | — | — | — |
| EPS (basic) | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 |
| EPS (diluted) | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 |
| Weighted avg. shares (diluted) | 67.81M | 48.16M | 26.99M | 26.31M | 12.26M |
| Balance sheet | |||||
| Cash & equivalents | $35.69M | $87.23M | $93.11M | $43.59M | $46.92M |
| Short-term investments | $65.39M | $63.69M | $13.69M | $79.98M | $89.56M |
| Current assets | $105.85M | $154.87M | $110.25M | $134.39M | $148.25M |
| PP&E, net | $288,000 | $199,000 | — | — | — |
| Total assets | $167.74M | $217.19M | $110.47M | $134.99M | $173.24M |
| Current liabilities | $6.98M | $4.93M | $2.83M | $6.10M | $6.03M |
| Total liabilities | $7.27M | $5.31M | $2.87M | $6.28M | $6.04M |
| Shareholders' equity | $160.47M | $211.88M | $107.60M | $128.72M | $167.20M |
| Shares outstanding | 47.77M | 67.26M | 27.70M | 26.57M | 26.57M |
| Cash flow statement | |||||
| Operating cash flow | -$54.36M | -$15.56M | -$20.60M | -$37.37M | -$36.07M |
| Capital expenditure | $186,000 | $0 | $0 | — | — |
| Free cash flow | -$54.54M | -$15.56M | -$20.60M | — | — |
| Investing cash flow | $2.83M | -$121.09M | $68.98M | $34.44M | -$114.97M |
| Financing cash flow | -$21,000 | $130.73M | $841,000 | $0 | $177.23M |
| Depreciation & amortization | $97,000 | $0 | — | — | — |
| Stock-based compensation | $8.05M | $5.56M | $12.81M | $6.99M | $3.74M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.